Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This 3-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in
preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the
study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks.
Assuming successful completion of Part 1, additional subjects will be randomized in Part 2 to
one of 2 lower doses of BCX7353 or placebo. Part 3 will enroll additional subjects into one
of three doses of BCX7353 or placebo. The study will compare the number of acute attacks in
each treatment group, as well as a number of other clinical and pharmacologic outcomes, and
the safety and tolerability of each dose of BCX7353 compared to placebo.